Page last updated: 2024-12-05

cytidine diphosphate choline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

CDP-choline(1-) : Conjugate base of CDP-choline(1+) arising from deprotonation of the diphosphate function. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cytidine Diphosphate Choline: Donor of choline in biosynthesis of choline-containing phosphoglycerides. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID25202509
CHEBI ID58779
MeSH IDM0005571
PubMed CID11583971
CHEMBL ID1231700
CHEBI ID16436
MeSH IDM0005571
PubMed CID13804
SCHEMBL ID221081
MeSH IDM0005571

Synonyms (102)

Synonym
cdp-choline(1-)
CHEBI:58779
5'-o-[({[2-(trimethylazaniumyl)ethoxy]phosphinato}oxy)phosphinato]cytidine
cidifos
NCGC00186005-01
MLS-0072913
Q27126045
cdp-choline (1-)
NCGC00186005-03
99470-45-8
cytidine 5'-(trihydrogen diphosphate), p'-[2-(trimethylammonio)ethyl] ester, inner salt, ion(1-)
DTXSID701116394
nsc-122002
cytidine 5'-diphosphate choline
nicholin
ip 302
CHEMBL1231700
ip-302
CHEBI:16436 ,
987-78-0
CDP-CHOLINE ,
citicoline
[(2r,3s,4r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl [hydroxy-[2-(trimethylazaniumyl)ethoxy]phosphoryl] phosphate
choline 5'-cytidine diphosphate
recofnan
choline cytidine diphosphate
niticolin
cytidine 5'-(choline diphosphate)
haocolin
cytidine choline diphosphate
cytidine diphosphate choline ester
cytidine 5'-(cholinyl pyrophosphate)
difosfocin
suncholin
ensign
cytidine diphosphorylcholine
colite
cytidine diphosphocholine
cyscholin
recognan
cytidine 5'-diphosphoric choline
startonyl
unii-536bq2jvc7
ubelin
536bq2jvc7 ,
cytidine 5-diphosphocholine
cytidine, 5'-pyrophosphate, ester with choline
citicoline [inn:jan]
cytidine 5'-(trihydrogen diphosphate), p'-(2-(trimethylammonio)ethyl) ester, inner salt
nsc 122002
somazina
einecs 213-580-7
brn 4170138
cdp-cholin [german]
citidoline
cytidindiphosphocholin [german]
citicolina [inn-spanish]
cytidine diphosphate cholin ester
citidin difosfato de colina [spanish]
choline, hydroxide, 5'-ester with cytidine 5'-(trihydrogen pyrophosphate), inner salt
cdp-colina [spanish]
cytidine 5'-(trihydrogen diphosphate), mono(2-(trimethylammonio)ethyl) ester, hydroxide, inner salt
citicolinum [inn-latin]
cytidoline
D00057
nicholin (tn)
citicoline (jp17/inn)
citicolina
cdp-colina
citicolinum
cytidindiphosphocholin
citidin difosfato de colina
5'-o-[hydroxy({[2-(trimethylammonio)ethoxy]phosphinato}oxy)phosphoryl]cytidine
cytidine 5'-diphosphocholine
cytidine diphosphate choline
citicholine
cyticholine
C00307
DB04290
[2-cytidylate-o'-phosphonyloxyl]-ethyl-trimethyl-ammonium
cdp-cholin
SCHEMBL221081
DTXSID9048431
W-100063
cytidine 5'-(trihydrogen diphosphate), p'-[2-(trimethylammonio)ethyl] ester, inner salt
RZZPDXZPRHQOCG-OJAKKHQRSA-N
AKOS025312525
{2-[({[(2r,3s,4r,5r)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl phosphonato)oxy]ethyl}trimethylazanium
cytidine diphosphate-choline
5'-o-[(s)-hydroxy({[2-(trimethylammonio)ethoxy]phosphinato}oxy)phosphoryl]cytidine
cdp-choline (neutral charge)
Q28529682
DB12153
C3438
2-(((((((2r,3s,4r,5r)-5-(4-amino-2-oxopyrimidin-1(2h)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)oxidophosphoryl)oxy)-n,n,n-trimethylethanaminium
mfcd00868097
CCG-269597
D81851
cytidine 5'-(trihydrogen diphosphate), p'-[2-(trimethylammonio)ethyl]ester, inner salt
A847982
cytidine diphosphate-choline;cdp-choline;cytidine 5'-diphosphocholine
EN300-7398882

Research Excerpts

Overview

Cytidine diphosphate choline (CDP-choline) is a cholinergic agent. It can both stimulate the cholinesterergic pathway and increase blood pressure.

ExcerptReferenceRelevance
"Cytidine diphosphate choline (CDP-choline) is a cholinergic agent that can both stimulate the cholinergic pathway and increase blood pressure. "( Cytidine diphosphate choline improves the outcome of cardiac arrest vs epinephrine in rat model.
Lei, Z; Qing, H; Yu, H, 2013
)
3.28

Effects

Cytidine diphosphate choline (CDP-choline) has been applied for treating acute craniocerebral injury and allowing recovery of consciousness after brain surgery.

ExcerptReferenceRelevance
"Cytidine diphosphate choline (CDP-choline) has been applied for treating acute craniocerebral injury and allowing recovery of consciousness after brain surgery. "( Efficient multi-enzyme-catalyzed CDP-choline production driven by an ATP donor module.
Chen, Y; Jiang, Y; Liu, D; Liu, Y; Niu, H; Wang, J; Xu, C; Yang, J; Yang, S; Ying, H, 2017
)
1.9
"Cytidine diphosphate choline (citicoline) has been previously shown to have efficacy in reducing the functional impairments associated with acute stroke. "( Long-term citicoline (cytidine diphosphate choline) use in patients with vascular dementia: neuroimaging and neuropsychological outcomes.
Browndyke, JN; Cohen, RA; Gordon, N; Moser, DJ; Paul, RH; Sweet, L, 2003
)
2.08

Toxicity

ExcerptReferenceRelevance
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
"The LD50 and LD0 of choline HCl and cytidine diphosphate choline (CDP-choline, citicoline, Somazina) by oral and intravenous route at equivalent doses of choline for both compounds were determined."( Dissimilar effects in acute toxicity studies of CDP-choline and choline.
Agut, J; Font, E; Ortiz, JA; Sacristán, A, 1983
)
0.54
" LD50 values were determined according to the cumulative method by Reed-Muench for mortality rate, and Pizzi's method for calculation of standard error."( CDP-choline: acute toxicity study.
Grau, T; Ortiz, JA; Romero, A; Sacristán, A, 1983
)
0.27
" It can therefore be concluded that CDP-choline does not cause any toxic effects under the chosen experimental conditions."( CDP-choline: 6-month study on toxicity in dogs.
Grau, T; Ortiz, JA; Romero, A; Sacristán, A, 1983
)
0.27
" All adverse reactions were monitored during the study period for safety assessment."( Efficacy and safety of oral citicoline in acute ischemic stroke: drug surveillance study in 4,191 cases.
Cho, HJ; Kim, YJ, 2009
)
0.35
" No adverse events were recorded."( Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study.
Castagna, A; Cotroneo, AM; Fantò, F; Gareri, P; Lacava, R; Malara, A; Monteleone, F; Putignano, S; Rocca, F, 2013
)
0.39

Pharmacokinetics

ExcerptReferenceRelevance
"A pharmacokinetic analysis of CDPcholine has been carried out treating either rats or dogs by oral administration with the double labelled molecule."( Biochemical rationale for the use of CDPcholine in traumatic brain injury: pharmacokinetics of the orally administered drug.
Cotticelli, MG; De Rosa, M; Galletti, P; Morana, A; Vaccaro, R; Zappia, V, 1991
)
0.28
"A rapid, simple, and sensitive high performance liquid chromatography-tandem mass spectrometry method (LC-ESI-MS/MS) was developed and validated for the determination and pharmacokinetic investigation of choline (CL), active metabolite of citicoline in human plasma using metformin (MF) as IS."( A rapid LC-ESI-MS/MS method for the quantitation of choline, an active metabolite of citicoline: Application to in vivo pharmacokinetic and bioequivalence study in Indian healthy male volunteers.
Dastidar, SG; Ghosh, D; Gupta, B; Haldar, D; Pal, TK; Sarkar, AK; Sarkar, P, 2012
)
0.38

Compound-Compound Interactions

ExcerptReferenceRelevance
" Citicoline 500 mg/kg and citicoline combined with rtPA also promoted functional recovery."( Effects of citicoline combined with thrombolytic therapy in a rat embolic stroke model.
Andersen, M; Boysen, G; Choi, SC; Meden, P; Overgaard, K, 1999
)
0.3
" In this study we report our experience with the neuronal protective effects of citicoline alone and in combination with urokinase in a model of focal ischemia."( Evaluating the efficacy of citicoline in embolic ischemic stroke in rats: neuroprotective effects when used alone or in combination with urokinase.
Li, Q; Shuaib, A; Yang, Y, 2000
)
0.31
"The effects of citicoline used either alone or in combination with hypothermia on the suppression of apoptotic processes after transient focal cerebral ischemia were investigated."( Effects of citicoline used alone and in combination with mild hypothermia on apoptosis induced by focal cerebral ischemia in rats.
Alkan, T; Korfali, E; Sahin, S; Temel, SG; Tolunay, S; Tureyen, K, 2010
)
0.36
"To investigate the efficacy of anisodine combined with cytidine-5'-diphosp-bocholine (citicoline) in the treatment of early optic nerve contusion."( Efficacy of cytidine-5'-diphosp-bocholine combined with compound anisodine in the treatment of early optic nerve contusion.
Huang, J; Huang, Y; Jiang, J; Wang, W; Zhang, J, 2012
)
0.38
" The patients in the intervention group additionally received anisodine in combination with citicoline."( Efficacy of cytidine-5'-diphosp-bocholine combined with compound anisodine in the treatment of early optic nerve contusion.
Huang, J; Huang, Y; Jiang, J; Wang, W; Zhang, J, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
"In this work, the bioavailability of the 14C-methyl-labelled cytidine diphosphate choline (CDP-Choline, citicoline, Somazina), has been studied by oral route, leading to the result that it is slowly and completely absorbed, with a very low urinary and fecal elimination, thus producing maintained blood levels."( Bioavailability of methyl-14C CDP-choline by oral route.
Agut, J; Font, E; Ortiz, JA; Sacristán, A, 1983
)
0.51
" When administered orally, it is absorbed almost completely, and its bioavailability is approximately the same as when administered intravenously."( CDP-choline: pharmacological and clinical review.
Frontera, G; Secades, JJ, 1995
)
0.29
" Absorption by the oral route is virtually complete, and bioavailability by the oral route is therefore approximately the same as by the intravenous route."( Citicoline: pharmacological and clinical review, 2006 update.
Lorenzo, JL; Secades, JJ, 2006
)
0.33
"Liposome encapsulation of active principles enhances their bioavailability to the brain."( Serial MRI study of the enhanced therapeutic effects of liposome-encapsulated citicoline in cerebral ischemia.
Agulla, J; Argibay, B; Castillo, J; Pérez-Mato, M; Ramos-Cabrer, P, 2011
)
0.37
"Cytidine 5'-diphosphocholine (CDP-choline or citicoline) is a highly bioavailable compound with potential benefits for aiding neural repair and increasing acetylcholine levels in the central and peripheral nervous system."( CDP-choline as a biological supplement during neurorecovery: a focused review.
Arenth, PM; Ricker, JH; Russell, KC; Zafonte, RD, 2011
)
0.37
" Pharmacokinetic studies suggested that it is well absorbed and highly bioavailable with oral dosing."( The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives.
Bruni, AC; Castagna, A; Cotroneo, AM; De Sarro, G; Gareri, P; Putignano, S, 2015
)
0.42

Dosage Studied

ExcerptRelevanceReference
" Likewise, the simultaneous dosing of both drugs, which causes an evident loss of weight in the animals, has demonstrated that an activation on the dopaminergic system is produced."( Effect of oral CDP-choline on acrylamide-induced lesion.
Agut, J; Font, E; Ortiz, JA; Sacristán, A, 1983
)
0.27
" Changes in perfusion pressure were recorded during a dose-response curve to ACh and after a 30 min perfusion with CDP-choline (1 mg/min)."( Effects of CDP-choline on acetylcholine-induced relaxation of the perfused carotid vascular beds of the rat.
Kramer, V; Miranda, HF; Paeile, C; Pelissier, T; Pinardi, G, 1994
)
0.29
" In the crossover study, the higher dosage of citicoline was clearly associated with improved immediate and delayed logical memory."( Citicoline improves verbal memory in aging.
Hochanadel, GS; Lieberman, HR; Myers, D; Spiers, PA; Wurtman, RJ, 1996
)
0.29
" The decrease in serum S100B protein level was correlated with the dosage of rhEPO."( Effect of recombinant human erythropoietin on serum S100B protein and interleukin-6 levels after traumatic brain injury in the rat.
Bian, XX; Qi, CP; Yuan, XS, 2010
)
0.36
" Ceraxon in daily dosage 2 g and cerebrolysin in daily dosage 10 ml during 10 days after the development of ischemic stroke led to the significantly better regression of neurological symptoms to the 21st day of disease compared to the control group."( [Comparative aspects of using neuroprotectors in the management of patients with ischemic stroke].
Ershov, VI, 2011
)
0.37
" Patients included in the study underwent brain computed tomography or magnetic resonance imaging, and plasma dosage of vitamin B12, folate, and thyroid hormones."( Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study.
Castagna, A; Cotroneo, AM; Fantò, F; Gareri, P; Lacava, R; Malara, A; Monteleone, F; Putignano, S; Rocca, F, 2013
)
0.39
"2%) an appropriate indication, dosage and duration were found."( [Prescription appropriateness: Indication of citicoline in Primary Care].
Álvarez Dorta, I; Gómez Rodríguez de Acuña, A; González Gómez, CM; Padilla Luz, A; Pérez Cánovas, ME; Reyes Rodríguez, JF,
)
0.13
" According to the results of clinical trials of the dosage regimen, citicoline administered in the dose of 1000 mg/day for 8 weeks accelerates the regression of hemiplegia; the intravenous injection in the dose of 750 mg/day for 10 days, starting with the first 48 hours of stroke onset symptoms, promotes the recovery of motor and cognitive functions; the intravenous injection in the dose of 1 g within 14 days improves the recovery of consciousness, general condition and functional status."( [The assessment of the efficacy of citicoline in the early and recovery stages of stroke].
Shavlovskaya, OA,
)
0.13
" The sample was randomized into 2 groups (29 each): the main sub-group received oral therapy with recognan for 30 days, while the daily dosage was 500 mg (5 ml)."( [Cognitive and emotional disorders in university students and teachers: the possibility of treatment with recognan (citicoline)].
Boldyrev, VG; Charikova, EV; Kanishcheva, AS; Logvinova, EM; Nemkova, SA; Petrova, EA; Ralleva, AV; Romanenko, NI; Savchenko, DV; Semenov, DV; Tsvetkov, DA; Vozvyshaeva, MY; Zagaryan, DA; Zavadenko, NN,
)
0.13
" The sample was randomized into 2 subgroups: the main group (n=20) received oral therapy with recognan (100 mg in 1 ml) for 30 days, while the daily dosage was 500 mg (5 ml)."( [Current treatment options for autonomic, cognitive and emotional disorders in patients with asthenic syndrome treated with recognan (citicoline)].
Nemkova, SA; Petrova, EA; Savchenko, DV; Semenov, DV; Vozvyshaeva, MY; Zavadenko, NN, 2019
)
0.51
" The main subgroup included29 people received oral recognan therapy (in solution, 100 mg in 1 ml) for 30 days, with a daily dosage of 500 mg (5 ml of solution)."( [The influence of the drug recognan (citicoline) on neurodynamic characteristics of mental activity in patients with mild cognitive impairment].
Nemkova, SA; Semenov, DV; Vozvyshaeva, MY; Zavadenko, NN, 2021
)
0.62
" The group was randomized into 2 subgroups: the main subgroup (26 people) received oral therapy with the drug Recognan, for 30 days, with the daily dosage of the drug being 500 mg."( [The effect of the use of the drug recognan (citicoline) on the state of higher mental functions in patients with mild cognitive impairment].
Nemkova, SA; Petrova, EA; Semenov, DV; Vozvyshaeva, MY; Zavadenko, NN, 2021
)
0.62
"These baseline-dependent nicotinic effects on early auditory information processing warrant different dosage and repeated administration assessments in patients with low baseline deviance detection levels."( An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine.
Blais, CM; Choueiry, J; Fisher, D; Knott, V; Labelle, A; Shah, D; Smith, D, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (3 Product(s))

Product Categories

Product CategoryProducts
Vitamins & Supplements3

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Divine Health Brain Zone Advanced -- 120 CapsulesDivine HealthVitamins & Supplements7,8 Dihydroxyflavone, Citicoline, Lithium, Tyrosine2024-11-29 10:47:42
Jarrow Formulas CDP Choline -- 250 mg - 120 CapsulesJarrow FormulasVitamins & SupplementsCiticoline2024-11-29 10:47:42
Jarrow Formulas Neuro Optimizer -- 120 CapsulesJarrow FormulasVitamins & SupplementsAcetyl L-Carnitine, Cytidine 5'-diphosphocholine, L-Glutamine, microcrystallinecellulose, Pantothenic Acid, Taurine2024-11-29 10:47:42

Roles (5)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
psychotropic drugA loosely defined grouping of drugs that have effects on psychological function.
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
psychotropic drugA loosely defined grouping of drugs that have effects on psychological function.
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
organophosphate oxoanionAn organic phosphoric acid derivative in which one or more oxygen atoms of the phosphate group(s) has been deprotonated.
nucleotide-(amino alcohol)s
phosphocholinesAny compound having phosphocholine as part of its structure.
nucleotide-(amino alcohol)s
phosphocholinesAny compound having phosphocholine as part of its structure.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (46)

PathwayProteinsCompounds
superpathway of phosphatidylcholine biosynthesis818
phosphatidylcholine resynthesis via glycerophosphocholine07
phosphatidylcholine biosynthesis I010
superpathway of choline biosynthesis1122
diacylglycerol biosynthesis (PUFA enrichment in oilseed)14
phosphatidylcholine biosynthesis II512
choline biosynthesis III912
ricinoleate biosynthesis17
superpathway of phospholipid biosynthesis II (plants)1731
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490
3q29 copy number variation syndrome012
phosphatidylcholine biosynthesis611
ricinoleate biosynthesis47
plasmalogen biosynthesis1024
phosphatidylcholine resynthesis via glycerophosphocholine310
superpathway of choline biosynthesis532
diacylglycerol biosynthesis (PUFA enrichment in oilseed)13
phosphatidylcholine biosynthesis I816
phosphatidylcholine biosynthesis II012
choline biosynthesis III513
cell-surface glycoconjugate-linked phosphocholine biosynthesis311
superpathway of phosphatidylcholine biosynthesis019
choline biosynthesis411
phospholipid biosynthesis (Kennedy pathway)414
MTHFR deficiency1515
Phospholipid Biosynthesis2529
Ether Lipid Metabolism412
Choline Metabolism1827
Lysolipid Incorporation into ER1023
Lysolipid Incorporation into ER PC(10:0/10:0)1016
Lysolipid Incorporation into ER PC(14:0/14:0)1023
Lysolipid Incorporation into ER PC(16:0/16:0)1024
Lysolipid Incorporation into ER PC(16:1(9Z)/16:1(9Z))1024
Lysolipid Incorporation into ER PC(16:1(11Z)/16:1(11Z))1017
Lysolipid Incorporation into ER PC(18:0/18:0)1024
Lysolipid Incorporation into ER PC(18:1(9Z)/18:1(9Z))1023
Lysolipid Incorporation into ER PC(18:2(9Z,11Z)/18:2(9Z,11Z))1019
Lysolipid Incorporation into ER PC(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))1023
Choline Biosynthesis II618
Glycine Betaine Biosynthesis II824
Phosphatidylcholine Biosynthesis615
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis614
Metabolism14961108
Metabolism of lipids500463
Phospholipid metabolism12242
Glycerophospholipid biosynthesis7439
Synthesis of PC2017
Glycerolipids and glycerophospholipids08
superpathway of phospholipid biosynthesis027
ester phospholipid biosynthesis021
Kennedy pathway012
Neurotransmitter release cycle021
Trans-sulfuration, one-carbon metabolism and related pathways053
Kennedy pathway from sphingolipids011
One-carbon metabolism and related pathways038
Choline biosynthesis III07

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
regulator of G-protein signaling 4Homo sapiens (human)Potency21.17210.531815.435837.6858AID504845
arylsulfatase AHomo sapiens (human)Potency16.94411.069113.955137.9330AID720538
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency30.13130.425612.059128.1838AID504536
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (29)

Assay IDTitleYearJournalArticle
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID683870Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as reversal of oxygen-glucose deprivation-induced neuronal damage at 100 uM by treated 4 hrs after OGD challenge measured after 24 hrs MTT assay relative to control2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Α-aryl-N-alkyl nitrones, as potential agents for stroke treatment: synthesis, theoretical calculations, antioxidant, anti-inflammatory, neuroprotective, and brain-blood barrier permeability properties.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID683879Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as reversal of oxygen-glucose deprivation-induced neuronal damage at 100 uM by treated 4 hrs after OGD challenge measured after 24 hrs by LDH release assay relative to contro2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Α-aryl-N-alkyl nitrones, as potential agents for stroke treatment: synthesis, theoretical calculations, antioxidant, anti-inflammatory, neuroprotective, and brain-blood barrier permeability properties.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID625294Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in O'Brien data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID683876Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as reversal of oxygen-glucose deprivation-induced neuronal damage at 250 uM by treated 4 hrs after OGD challenge measured after 24 hrs by LDH release assay relative to contro2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Α-aryl-N-alkyl nitrones, as potential agents for stroke treatment: synthesis, theoretical calculations, antioxidant, anti-inflammatory, neuroprotective, and brain-blood barrier permeability properties.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID683873Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as reversal of oxygen-glucose deprivation-induced neuronal damage at 10 uM by treated 4 hrs after OGD challenge measured after 24 hrs MTT assay relative to control2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Α-aryl-N-alkyl nitrones, as potential agents for stroke treatment: synthesis, theoretical calculations, antioxidant, anti-inflammatory, neuroprotective, and brain-blood barrier permeability properties.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (924)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990300 (32.47)18.7374
1990's140 (15.15)18.2507
2000's172 (18.61)29.6817
2010's214 (23.16)24.3611
2020's98 (10.61)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.76 (24.57)
Research Supply Index7.02 (2.92)
Research Growth Index4.61 (4.65)
Search Engine Demand Index36.71 (26.88)
Search Engine Supply Index4.00 (0.95)

This Compound (16.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Trials132 (13.35%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Reviews97 (9.81%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Case Studies15 (1.52%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Observational8 (0.81%)0.25%
Other10 (100.00%)84.16%
Other5 (100.00%)84.16%
Other737 (74.52%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (46)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Improving Sleep and Alzheimer's Disease (AD) Biomarkers: A Pilot Randomized Clinical Trial (RCT) of Citicoline [NCT06029894]100 participants (Anticipated)Interventional2023-12-16Recruiting
Improving Sleep and Cognition in Alzheimer's Disease: A Pilot RCT of Citicoline [NCT05200208]20 participants (Anticipated)Interventional2022-07-27Recruiting
A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Assess the Cognitive Effects of a Citicoline Supplement (Cognizin®) on Attention in Healthy Men and Women [NCT04967157]148 participants (Actual)Interventional2021-09-08Completed
Efficacy of Citicoline as Neuroprotector in Preterm; A Randomized Controlled Trial [NCT03966170]Phase 340 participants (Anticipated)Interventional2019-05-01Recruiting
Role of Citicoline in Treatment of Newborns With Hypoxic Ischemic Encephalopathy [NCT03181646]Phase 350 participants (Anticipated)Interventional2017-06-15Recruiting
The Combination of Citicoline and Omega-3 on Attention in Healthy Subjects [NCT03444662]70 participants (Actual)Interventional2018-06-12Completed
Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy [NCT01338389]21 participants (Actual)Interventional2012-06-25Completed
Efficacy of Citicoline as Neuroprotector in Neonates Exposed to Hypoxia: A Randomized Controlled Trial [NCT03949049]Phase 340 participants (Anticipated)Interventional2019-02-01Recruiting
Clinical Medication Development for Bipolar Disorder and Alcohol Use Disorders [NCT02582905]Phase 496 participants (Actual)Interventional2016-05-31Completed
CDP-Choline and Working Memory After TBI: A Neuroimaging Study. [NCT00727246]Phase 219 participants (Actual)Interventional2009-03-31Completed
Neurobehavioral and Immune Effects of Citicoline in Youth Alcohol Use Disorder [NCT05870111]Phase 248 participants (Anticipated)Interventional2024-02-29Not yet recruiting
Effects of CDP-Choline on Gating and Cognitive Deficits in First Episode Schizophrenia [NCT02088983]Phase 240 participants (Anticipated)Interventional2014-04-30Not yet recruiting
Supplemental Citicoline Administration to Reduce Lung Injury Efficacy Trial (SCARLET) [NCT05881135]Phase 1/Phase 280 participants (Anticipated)Interventional2023-06-06Recruiting
Evaluation of the Effect of Citicoline (Cebrolux 800 mg) and Docosahexaenoic Acid (DHA) Compound (BrudyPio 1.5 g) on the Visual Function of Patients With Glaucoma With a Pilot Study [NCT05527106]73 participants (Actual)Interventional2015-03-12Completed
Interventions to Test the Alpha7 Nicotinic Receptor Model in Schizophrenia [NCT00509067]Phase 243 participants (Actual)Interventional2007-11-30Completed
Citicoline Effects on Cortical Membrane Structure and Function [NCT02705066]61 participants (Actual)Interventional2016-03-31Completed
A Feasibility Study of Ramelteon and Citicoline for Delirium in a General Inpatient Hospital Population [NCT02840591]Phase 40 participants (Actual)Interventional2016-07-31Withdrawn(stopped due to Stopped the study due to feasibility issues, no enrollment has taken place.)
Neuroprotection and Neuroenhancement in a Model of Optic Nerve Neurodegeneration (Non Arteritic Ischemic Optic Neuropathy): Study of Morpho-functional Changes Related to Treatment With Citicoline Oral Solution [NCT03758118]40 participants (Actual)Interventional2017-02-20Completed
Superselective Citicoline And Verapamil for Ischemic Neuroprotection and Greater Effective Response (SCAVINGER) in the Kentucky Regional Population: A Clinical and Translational Study [NCT02823106]Phase 10 participants (Actual)Interventional2016-08-31Withdrawn(stopped due to Study put on clinical hold by FDA. Sponsor decided to no pursue the study.)
A Double-blind, Placebo-controlled Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence [NCT00377299]60 participants (Actual)Interventional2006-10-31Completed
Evaluation of Citicoline Concentration in Human Vitreous After Topical Administration: a Cross-sectional Study [NCT04003090]26 participants (Actual)Interventional2018-03-21Completed
[NCT01582113]Early Phase 184 participants (Actual)Interventional2012-06-30Completed
[NCT01007539]Phase 331 participants (Actual)Interventional2009-11-30Completed
Navigation Brain Stimulation (NBS) for Evaluation of the Neuroprotective Drug Efficiency in Patients After Ischemic Stroke. [NCT01388738]Phase 330 participants (Anticipated)Interventional2011-01-31Completed
Phase 4 Study of Evaluation of Neural Conduction Along the Visual Pathways Before and After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases [NCT00404729]Phase 460 participants (Actual)Interventional2005-02-28Completed
Citicoline Treatment of Methamphetamine Dependence [NCT00950352]Phase 3104 participants (Actual)Interventional2010-01-31Completed
Citicoline and Omega-3 Fatty Acid Effects in Veterans With TBI [NCT01515917]0 participants (Actual)Interventional2013-11-30Withdrawn
Modulation of Neuronal Connettivity Along the Visual Pathways in Patients Affected by Glaucoma Throug Treatment With Citicoline Oral Solution: Multimodal Morpho-funcional Study [NCT05315206]60 participants (Anticipated)Interventional2022-01-25Recruiting
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial of Citicoline as an add-on Therapy Will be Conducted in 200 Outpatients With Bipolar I Disorder and Cocaine Dependence. [NCT00619723]Phase 4130 participants (Actual)Interventional2008-04-30Completed
Citicoline, Creatine, and Omega-3 Effects in Middle Age Women [NCT01502813]40 participants (Actual)Interventional2012-02-01Completed
Cytidine-5'-Diphosphate-choline Treatment in Amphetamine Type Stimulant-using Adolescents [NCT02630069]Phase 2160 participants (Anticipated)Interventional2015-03-31Recruiting
Nimodipine for Treating Acute Massive Cerebral Infarction: a Randomized, Double-blind, Controlled Clinical Study [NCT02248233]Phase 472 participants (Actual)Interventional2014-10-31Completed
A Phase III Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Trial of the Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma [NCT05710198]Phase 31,000 participants (Anticipated)Interventional2023-04-01Not yet recruiting
Cannabis Dependence: Imaging and Medication Development - 1 [NCT00158249]Phase 221 participants (Actual)Interventional2009-09-30Completed
Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) : Pattern Electroretinography Study [NCT03046693]Phase 438 participants (Actual)Interventional2017-01-16Completed
A Pilot Trial of Citicoline in Individuals With mTBI [NCT01591759]Phase 20 participants (Actual)Interventional2012-04-30Withdrawn(stopped due to Our citicoline supply expired and the exact product has discontinued.)
A Double-blind, Placebo-controlled Trial of Citicoline add-on Therapy in Patients With a History of Mania or Hypomania and Cocaine Abuse/Dependence [NCT00223236]Phase 344 participants (Actual)Interventional2010-07-31Completed
Citicoline in the Treatment of Acute Ischemic Stroke. An International Randomized Multicenter Placebo-controlled Study [NCT00331890]Phase 32,298 participants (Actual)Interventional2006-10-31Terminated(stopped due to With 2078 patients, a statistical stopping boundary has now been crossed)
The Impact of Air Travel on Passenger Cognitive Functions [NCT04802785]Phase 2/Phase 350 participants (Anticipated)Interventional2021-06-30Not yet recruiting
Effect of the Fixed Combination Citicoline 500 mg Plus Homotaurine 50 mg on Pattern Electroretinogram in Well Controlled Primary Open Angle Glaucoma: A Multicenter, Prospective, Randomized, Single Blind, Cross-over Study [NCT04422743]63 participants (Actual)Interventional2018-01-25Terminated(stopped due to due to covid 19 pandemy)
Citicoline for Alcohol Dependence [NCT02074735]Phase 462 participants (Actual)Interventional2014-04-30Completed
Citicoline Brain Injury Treatment Trial [NCT00545662]Phase 31,213 participants (Actual)Interventional2007-07-31Terminated(stopped due to Trial stopped due to futility.)
The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma [NCT04020705]90 participants (Actual)Interventional2015-09-22Completed
Citicholine-Amantadine Trial in Traumatic Brain Injury [NCT03430817]Phase 445 participants (Actual)Interventional2017-12-07Active, not recruiting
A Parallel, Double-Blind Study to Assess the Cognitive Effects of a Citicoline Supplement (Cognizin®) in Men and Women With Age-Associated Memory Impairment [NCT03369925]100 participants (Actual)Interventional2018-01-02Completed
Citicoline in Acute Ischemic Stroke [NCT05154903]Phase 3200 participants (Anticipated)Interventional2021-07-22Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00158249 (2) [back to overview]Marijuana Use
NCT00158249 (2) [back to overview]Neurocognitive Function
NCT00223236 (4) [back to overview]Cocaine Use Determined by Urine Analysis
NCT00223236 (4) [back to overview]Inventory of Depressive Symptomatology Self Report (IDS-SR).
NCT00223236 (4) [back to overview]Rey Auditory Verbal Learning Test(RAVLT)
NCT00223236 (4) [back to overview]Young Mania Rating Scale(YMRS).
NCT00377299 (5) [back to overview]Amphetamine Craving
NCT00377299 (5) [back to overview]Amphetamine Use
NCT00377299 (5) [back to overview]Depression Symptoms
NCT00377299 (5) [back to overview]Hopkins Auditory Verbal Learning Test (HVLT)
NCT00377299 (5) [back to overview]Stroop Color Word Test
NCT00509067 (3) [back to overview]Clinical Global Impression
NCT00509067 (3) [back to overview]MATRICS Verbal Learning and Memory
NCT00509067 (3) [back to overview]Negative Symptoms Measured on Positive and Negative Syndrome Scale (PANSS)
NCT00545662 (1) [back to overview]Functional and Cognitive Outcome
NCT00619723 (3) [back to overview]Depressive Symptoms Measured Using the Hamilton Rating Scale for Depression (HRSD)
NCT00619723 (3) [back to overview]Manic Symptoms Measured Using Young Mania Rating Scale (YMRS)
NCT00619723 (3) [back to overview]Percentage of Participants With Presence of a Cocaine-Positive Urine Screen
NCT00727246 (2) [back to overview]Cognitive Composite Score for Group of Subjects With TBI and Healthy Controls Matched by Age, Education, and Treatment Group.
NCT00727246 (2) [back to overview]Cognitive Composite Score for Group of Subjects With TBI and Unmatched Healthy Controls
NCT00950352 (1) [back to overview]Methamphetamine Dependent Subjects Treated With Citicoline vs Placebo
NCT01502813 (2) [back to overview]Change From Baseline in California Verbal Learning Test (CVLT) That Measure Attention and Memory at 14 Days
NCT01502813 (2) [back to overview]Change From Baseline in WAIS-IV Block Design Subtest A That Measures Attention and Memory at 28 Days
NCT02074735 (1) [back to overview]Heavy Drinking Days Per Week
NCT03758118 (5) [back to overview]Change From Baseline in Optic Nerve Function at 9 Months
NCT03758118 (5) [back to overview]Change From Baseline in Optic Nerve Morphology at 9 Months
NCT03758118 (5) [back to overview]Change From Baseline in Retinal Ganglion Cells Function at 9 Month
NCT03758118 (5) [back to overview]Change From Baseline in Visual Acuity at 9 Month
NCT03758118 (5) [back to overview]Change From Baseline in Visual Field Defects at 9 Months

Marijuana Use

(NCT00158249)
Timeframe: Measured for 8 weeks of treatment

InterventionReported uses per day (Mean)
Placebo2.5
Citicoline3.9

[back to top]

Neurocognitive Function

Multiple Source Interference Test (MSIT) (NCT00158249)
Timeframe: Before and after 8 weeks of treatment

InterventionAccuracy percent improvement (Mean)
Placebo32.45
Citicoline16.08

[back to top]

Cocaine Use Determined by Urine Analysis

Urine drug screens were administered at each visit to detect cocaine in urine. If negative according to urine analysis, it is determined as no cocaine use and if positive, cocaine use. Percentage of participants with no cocaine detected in urine at exit is an outcome measuring treatment effectiveness. Exit week is defined as the last week of treatment. It varied between 2 week an 12 weeks with an average exit week of 10 week and 7 week for the citicoline treatment and placebo groups, respectively. Allowing unequal week of treatment period in measuring outcome enables us to include most participants due to a low retention rate in the end of the study period, 12 weeks. (NCT00223236)
Timeframe: Biweekly (visit) urine drug screens

Interventionpercentage of participants no cocaine (Number)
Citicoline62.50
Placebo50.00

[back to top]

Inventory of Depressive Symptomatology Self Report (IDS-SR).

The IDS-SR is a 30 item self report used to assess the severity of depressive symptoms. The each item has a 4-likert scale, 0 to 3, with 3 representing the worst symptom. The total score of IDS-SR is calculated as a sum of each item score. The range of possible score is between 0 and 90, 0 as no symptom and 90 the worst symptom. The higher the score, the more severe the depression. Exit week is defined as the last week of treatment. It varied between 2 week an 12 weeks with an average exit week of 10 week and 7 week for the citicoline treatment and placebo groups, respectively. Allowing unequal week of treatment period in measuring outcome enables us to include most participants due to a low retention rate in the end of the tudy period, 12 weeks. The outcome was measured by change in scores between baseline and exit (exit - baseline). (NCT00223236)
Timeframe: Change in scores between baseline and exit (exit - baseline).

Interventionunits on scale (Mean)
Citicoline-20.54
Placebo-11.89

[back to top]

Rey Auditory Verbal Learning Test(RAVLT)

The RAVLT consists of 15 nouns read aloud for five consecutive trials with each trial followed by a free-recall trial. The total score is the total number of words recalled through the five trials. Normative RAVLT T-scores was used. the higher T score, the better memory. Exit week is defined as the last week of treatment. It varied between 2 week an 12 weeks with an average exit week of 10 week and 7 week for the citicoline treatment and placebo groups, respectively. Allowing unequal week of treatment period in measuring outcome enables us to include most participants due to a low retention rate in the end of the study period, 12 weeks. The outcome was measured by change in RAVLT T scores between baseline and exit (exit - baseline). (NCT00223236)
Timeframe: Change in T scores between baseline and exit (exitT score - baseline T score).

InterventionT score (Mean)
Citicoline7.06
Placebo3.14

[back to top]

Young Mania Rating Scale(YMRS).

The YMRS questionnaire has 11 items with scale range 0 to 4 for 7 items and 0 to 8 for 4 items. 0=normal and and 4 or 8 =most abnormal. The total possible score is 0 to 60, 0 being no symptom and 60 the worst symptom. The higher the score, the worse the mania symptoms are. Exit week is defined as the last week of treatment. It varied between 2 week an 12 weeks with an average exit week of 10 week and 7 week for the citicoline treatment and placebo groups, respectively. Allowing unequal week of treatment period in measuring outcome enables us to include most participants due to a low retention rate in the end of the study period, 12 weeks. The outcome was measured by change in scores between baseline and exit (exit - baseline). (NCT00223236)
Timeframe: Baseline to exit (exit score - baseline score)

Interventionunits on a scale (Mean)
Citicoline-2.00
Placebo-2.88

[back to top]

Amphetamine Craving

Visual Analog Scale (VAS) assessing Methamphetamine craving with a 1-100 scale.Higher values on the VAS scale indicate a higher Methamphetamine craving(worse outcome). (NCT00377299)
Timeframe: 12 Weeks

Interventionscores on a scale (Mean)
Citicoline31.9
Placebo44.1

[back to top]

Amphetamine Use

Participant reported days per 7-day week of methamphetamine use. (NCT00377299)
Timeframe: 12 weeks

Interventiondays per week (Mean)
Citicoline2.9
Placebo2.3

[back to top]

Depression Symptoms

Inventory of Depressive Symptomatology-Clinician Rated (IDS-C), (a clinician-administered depression scale) is used to assess the severity of depressive symptoms.Scores can range from 0 to 84. The higher the score, the worse the depressive symptoms(worse outcome). (NCT00377299)
Timeframe: 12 weeks

Interventionscores on a scale (Mean)
Citicoline26.2
Placebo33.1

[back to top]

Hopkins Auditory Verbal Learning Test (HVLT)

The Hopkins Auditory Verbal Learning Test (HVLT) is a measure of cognition (memory/recall). Raw scores are derived for Total Recall, Delayed Recall, Retention (% retained), and a Recognition Discrimination Index. Raw scores are calculated into T-scores. T-scores are standardized scores on each dimension for each type. A score of 50 represents the mean. A difference of 10 from the mean indicates a difference of one standard deviation. Thus, a score of 60 is one standard deviation above the mean, while a score of 30 is two standard deviations below the mean. (NCT00377299)
Timeframe: 12 weeks

InterventionT score (Mean)
Citicoline38.5
Placebo47.5

[back to top]

Stroop Color Word Test

The Stroop Color Word Test measures the individual's ability to separate the word and color naming stimuli thus the ability to sort information from the environment and selectively react to this information. The scoring is a measure of time to complete 100 items and the numbers of items that can be completed. THe scores are converted into T-scores which have a mean of 50 and a standard deviation of 10. (NCT00377299)
Timeframe: 12 weeks

InterventionT score (Mean)
Citicoline56.2
Placebo54.3

[back to top]

Clinical Global Impression

The score for each subject was the mean rating on the severity item. The score of the item ranged from 1 (normal) to 7 (among most severely ill). (NCT00509067)
Timeframe: Measured at Baseline and Weeks 4, 8, 12, and 16

,
Interventionunits on a scale (Mean)
BaselineWeek 4Week 8Week 12Week 16
Galantamine and CDP-choline Group4.3243.673.873.8
Placebo Group4.383.924.0443.68

[back to top]

MATRICS Verbal Learning and Memory

The measure of verbal learning and memory is the Hopkins Verbal Learning Test. The score for each subject is the sum of the total number of words recalled correctly for Trials 1, 2, and 3. The measure is the mean of these scores at baseline, Week 8, and Week 16. (NCT00509067)
Timeframe: Measured at Baseline and Weeks 8 and 16

,
Interventionraw scores (Mean)
BaselineWeek 8Week 16
Galantamine and CDP-choline Group20.521.823.0
Placebo Group20.621.220.4

[back to top]

Negative Symptoms Measured on Positive and Negative Syndrome Scale (PANSS)

The score for each subject was the sum of the ratings for five items on the negative-symptom subscale of the PANSS: 1) blunted affect, 2) emotional withdrawal, 3) poor rapport, 4) passive/apathetic social withdrawal, and 5) lack of spontaneity and flow of conversation. Each item (symptom) is rated on a scale from 1 = absence of negative symptom to 7 = extreme negative symptom. The sum of the ratings for the five items range from 5 to 35, with higher scores indicating more severe symptoms. The primary outcome measure is the mean of the sum of these ratings across subjects. (NCT00509067)
Timeframe: Measured at Baseline and Weeks 4, 8, 12, and 16

,
Interventionunits on a scale (Mean)
BaselineWeek 4Week 8Week 12Week 16
Galantamine/CDP Choline17.6317.0613.9314.9313.93
Placebos for Galantamine/CDP Choline18.2917.0817.2617.3216.05

[back to top]

Functional and Cognitive Outcome

The primary outcome of this study was analyzed using a global statistic of the Network Core Battery. There were 9 scales: California Verbal Learning Test II (CVLT-II); Controlled Oral Word Association Test (COWAT); Digit Span (DS); Glasgow Outcome Scale Extended (GOSE); Processing Speed Index (PSI); Stroop Test 1 and 2 (ST1&2); and Trail Making Test part A and B (TMT parts A and B). Each scale was assigned cut-off for good outcome: GOSE>7, CVLT>36, PSI>85, TMT part A <42, TMT part B<138.1, DS>7.15, ST1<60.29, ST2<151.47, COWAT>32.5. Logistic regression was used to estimate the global OR. (NCT00545662)
Timeframe: 90 days

,
Interventionpercentage of participants (Number)
Glasgow Outcome Scale - ExtendedCalifornia Verbal Learning TestProcessing Speed IndexTrail Making ATrail Making BDigit SpanStroop Task 1Stroop Task 2Controlled Oral Word Association Test
Control35.5660.4853.2861.9671.0584.0267.9566.5942.68
Treatment35.4357.7152.6864.9674.4486.5065.3168.2937.32

[back to top]

Depressive Symptoms Measured Using the Hamilton Rating Scale for Depression (HRSD)

As part of HRSD, the patient is rated by a clinician on 17 items that measure depressive symptom severity. The total score is calculated by summing the responses across all items. Lower scores (closer to 0) indicate the absence of depressive symptoms, while higher scores indicate the presence of depressive symptoms. Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine are scored from 0-2 (0 = not present; 2 = severe). The scale range of scores is 0-52. (NCT00619723)
Timeframe: 12 Weeks

Interventionunits on a scale (Mean)
Citicoline17.9
Placebo18.0

[back to top]

Manic Symptoms Measured Using Young Mania Rating Scale (YMRS)

The Young Mania Rating Scale (YMRS) is a clinician-rated scale that has 11 items and is based on the patient's subjective report of his or her clinical condition over the previous 48 hours. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. These four items are given twice the weight of the others to compensate for poor cooperation from severely ill patients. The total score is calculated by summing answers to all the item on the scale, with a higher score indicative of more severe mania symptoms. The scale total score ranges from 0 (absence of manic symptoms) to 60 (severe manic symptoms). (NCT00619723)
Timeframe: 12 weeks

Interventionunits on a scale (Mean)
Citicoline10.2
Placebo10.1

[back to top]

Percentage of Participants With Presence of a Cocaine-Positive Urine Screen

Cocaine use frequency was measured by the presence or absence of a cocaine-positive urine screen. Drug screens were obtained thrice-weekly for 12 weeks. All participants who completed the baseline assessment and at least one additional assessment were included in the primary analysis. Missing data were imputed as cocaine positive. (NCT00619723)
Timeframe: 12 weeks

Interventionpercentage of participants (Number)
Citicoline59.0
Placebo49.2

[back to top]

Cognitive Composite Score for Group of Subjects With TBI and Healthy Controls Matched by Age, Education, and Treatment Group.

.A mean index score created as a composite cognitive performance across domains. Purpose was to serve as a measure of overall cognitive functioning for data analysis. A higher T-score indicates a higher level of cognitive function. Due to matching criteria of age range, gender and education level, as well as the small number of subjects with TBI who complete the study (n = 5), matched groups required a reduction to 2 subjects per group for analysis as planned per protocol. Due to the small number of subjects in this study overall, although analyses were run, results should be considered with caution. (NCT00727246)
Timeframe: 6 weeks

InterventionT-score (Mean)
Participants With TBI Who Received CDP-Choline42.750
Participants With TBI Who Received Placebo50.500
Control Participants Who Received CDP-Choline49.500
Control Participants Who Received Placebo55.000

[back to top]

Cognitive Composite Score for Group of Subjects With TBI and Unmatched Healthy Controls

A mean index score created as a composite cognitive performance across domains. Purpose was to serve as a measure of overall cognitive functioning for data analysis. Higher T-scores indicate higher levels of cognitive functioning. Due to the small number of subjects in this study, this second analysis was completed using the same number of subjects in the TBI and control groups, but without matching so that a slightly larger number of subject's data could be utilized. Although analyses were run, due to the very small number of participants in this study, results should be considered with caution. (NCT00727246)
Timeframe: 6 weeks

InterventionT-score (Mean)
Participants With TBI Who Received CDP-Choline55.750
Participants With TBI Who Received Placebo50.167
Control Participants Who Received CDP-Choline53.000
Control Participants Who Received Placebo55.000

[back to top]

Methamphetamine Dependent Subjects Treated With Citicoline vs Placebo

Total Amount of Methamphetamine consumed by the participants after 8-9 weeks of treatment. Methamphetamine was assessed twice weekly. (NCT00950352)
Timeframe: 8 weeks, assessed twice weekly starting week1

Interventiontotal amount consumed in grams (Mean)
Citicoline0.3025
Placebo0.3850

[back to top]

Change From Baseline in California Verbal Learning Test (CVLT) That Measure Attention and Memory at 14 Days

List B in the California Verbal Learning Test (CVLT) score range 1-16; the score is the number of words recalled so higher scores = better performance/more words recalled. (NCT01502813)
Timeframe: Baseline and 14 days from baseline

Interventionscore on a scale (Median)
Citicoline, Creatine, and Omega-3 Arm10

[back to top]

Change From Baseline in WAIS-IV Block Design Subtest A That Measures Attention and Memory at 28 Days

WAIS-IV Block Design Subtest A test of visuoconstructional ability is recognized as a test of visuospatial planning and function. It has been shown to be correlated with measures of general intellectual ability. The score range for this measure is 0-129. A score of 90-110 is average for a standard score. The higher the score the better the outcome. (NCT01502813)
Timeframe: Baseline and 28 days from baseline

InterventionScore on a scale (Mean)
Citicoline, Creatine, and Omega-3 Arm98

[back to top]

Heavy Drinking Days Per Week

"Heavy drinking days are defined as 4 or more drinks for women, 5 or more drinks for men in a single day. Participants self-reported the type and amount of alcohol consumed during each assessment period. From this information, number of standard drinks per day was calculated using the following formula: (number of drinks) x (oz per drink) x (alcohol by volume or ABV). The average number of heavy drinking days was calculated by dividing the number of heavy drinking days per week by the number of days in the assessment period." (NCT02074735)
Timeframe: 12 weeks

Interventiondays/week (Mean)
Placebo0.23
Citicoline0.33

[back to top]

Change From Baseline in Optic Nerve Function at 9 Months

Visual Evoked Potentials recordings. Shortening of the main parameter P100 Implicit time measured in milliseconds (NCT03758118)
Timeframe: 9 months vs baseline

Interventionmilliseconds (Mean)
NAION Patients OS-Citicoline Treated127.05
NAION Patients Untreated126.88

[back to top]

Change From Baseline in Optic Nerve Morphology at 9 Months

Reduction of Overall Retinal Nerve Fiber Thickness by Optical Coherence Tomography measured in micron (NCT03758118)
Timeframe: 9 months vs baseline

Interventionmicron (Mean)
NAION Patients OS-Citicoline Treated57.71
NAION Patients Untreated63.99

[back to top]

Change From Baseline in Retinal Ganglion Cells Function at 9 Month

Pattern-Electroretinogram recordings. Increase of P50-N95 amplitude (measured in microvolt) (NCT03758118)
Timeframe: 9 months vs Baseline

Interventionmicrovolt (Mean)
NAION Patients OS-Citicoline Treated1.32
NAION Patients Untreated1.38

[back to top]

Change From Baseline in Visual Acuity at 9 Month

Increase of Visual Acuity evaluated by Early Treatment Diabetic Retinopathy Study (ETDRS) charts and measured as a logarithm of the minimum angle of resolution (LogMAR) (NCT03758118)
Timeframe: 9 months vs baseline

InterventionLogMAR (Mean)
NAION Patients OS-Citicoline Treated-0.0574
NAION Patients Untreated0.0535

[back to top]

Change From Baseline in Visual Field Defects at 9 Months

improvement of the visual field by static perimetry (increase of the main indexes Mean Deviation measured in dB). (NCT03758118)
Timeframe: 9 months vs baseline

InterventiondB (Mean)
NAION Patients OS-Citicoline Treated-15.61
NAION Patients Untreated-13.02

[back to top]